by Raynovich Rod | Jun 27, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-3 July 5 11a EDT Rally in speculative biotech stocks with XBI up1.85% to $77 handle. Early movers: AGEN, CRSP, CYRX, DNA, QDEL, ROIV, VCYT all on our focus list. Added to Moderna (MRNA) at $153. Market indices in red on recession fears with S%P 500 down 1.9%...
by Raynovich Rod | Jun 21, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 June 22…Market ends trading day flattish with usual choppiness focused on macro after Powell speaks. Recession fears dominate with energy stocks down again. Bright spot is healthcare sector led by large caps with nibbling in beaten- up small caps. Like...
by Raynovich Rod | Jun 13, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 6/20 10:30p PDT…. Futures are up poised for a nice rally tomorrow. Last week even healthcare stocks hit new YTD lows with the XLV down 14.91% YTD now at $119.89. Even large cap biopharma stocks have sold off over the past month. ==== Update-1 FED raises...
by Raynovich Rod | May 30, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks, Macro
Update-4 June 8 Sideways market with trading opportunities in Small cap biotechs. With markets so choppy day to day and volatile within day it is hard to trade. But in my most recent trades I am more hopeful with this buying window. The bellwether remains XBI which...
by Raynovich Rod | May 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 …5/13 Many analysts see today’s sharp upside action as an oversold rally from 2022 lows.The highest risk stocks soared along with large cap tech stocks. NASDAQ was up 3.75%,S&P up 2.3%, DOW up 1.42%. To some extent this shifted action away...
by Raynovich Rod | Feb 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
At close 2/11: Another crappy day now with Ukraine Crisis coming to fore. But some large cap biopharmas get green: BMY. GILD, REGN up 3.27%, and PFE. Nibbled on NeuroCrine (NBIX) at $85. Update-3 2/11 12p EST…Small caps fight the headwinds but “hold the...
by Raynovich Rod | Nov 7, 2021 | 2020-21 Life Science Portfolios, Biopharmaceuticals, Macro
11/9…at close..NASDAQ lower by 0.6% after 12 day win streak. IBB down 1.34% coinciding with Biden drug pricing proposal? Large caps mixed but no sell-off. Sold my ARKG and XBI trades at about 3% profit. Vaccine stocks weak. Mid-cap focus stocks weak. Mid-cap...
by Raynovich Rod | Oct 11, 2021 | 2020-21 Life Science Portfolios, Biopharmaceuticals, Macro
Update-3 10/15/21 10/15/21…9/20a Broad rally carries biotech stocks off recent bottom with IBB to $155 to $157.87…XBI up 1.67% to $127.10. But technology shares gave been stronger. Retail sales rise 0.7% despite supply chain issues. Pre-market looks good...
by Raynovich Rod | Mar 29, 2021 | 2020 Rayno Tools and Diagnostics Portfolio, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-3 April 5 12:45p EDT…Biotech sector lags strong market today as S&P and DOW hit new highs as of mid-day trading.NASDAQ up 1.49%! It looks like re-opening stocks are favored over long-term plays in biopharma that have few catalysts.Tech is strong as...
by Raynovich Rod | Mar 22, 2021 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Final Close 5/26: Dow up 1.39% at 33072, S&P 500 up 1.66% at 3974, , Nasdaq up 1.24% at13138 , Russell 2000 down 2.89%. IBB stable at close. Update-3 March 26. 3p EDT Another day of selling for biotech; I’ll look for trades over the weekend. IBB down 0.98 to...
